Muutke küpsiste eelistusi

Behavioral Neurobiology of Psychedelic Drugs Softcover reprint of the original 1st ed. 2018 [Pehme köide]

Edited by , Edited by , Edited by
  • Formaat: Paperback / softback, 430 pages, kõrgus x laius: 235x155 mm, kaal: 676 g, 158 Illustrations, color; 38 Illustrations, black and white; X, 430 p. 196 illus., 158 illus. in color., 1 Paperback / softback
  • Sari: Current Topics in Behavioral Neurosciences 36
  • Ilmumisaeg: 19-Jan-2019
  • Kirjastus: Springer-Verlag Berlin and Heidelberg GmbH & Co. K
  • ISBN-10: 3662585634
  • ISBN-13: 9783662585634
Teised raamatud teemal:
  • Pehme köide
  • Hind: 215,47 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Tavahind: 253,49 €
  • Säästad 15%
  • Raamatu kohalejõudmiseks kirjastusest kulub orienteeruvalt 2-4 nädalat
  • Kogus:
  • Lisa ostukorvi
  • Tasuta tarne
  • Tellimisaeg 2-4 nädalat
  • Lisa soovinimekirja
Behavioral Neurobiology of Psychedelic Drugs Softcover reprint of the original 1st ed. 2018Suurem pilt
  • Formaat: Paperback / softback, 430 pages, kõrgus x laius: 235x155 mm, kaal: 676 g, 158 Illustrations, color; 38 Illustrations, black and white; X, 430 p. 196 illus., 158 illus. in color., 1 Paperback / softback
  • Sari: Current Topics in Behavioral Neurosciences 36
  • Ilmumisaeg: 19-Jan-2019
  • Kirjastus: Springer-Verlag Berlin and Heidelberg GmbH & Co. K
  • ISBN-10: 3662585634
  • ISBN-13: 9783662585634
Teised raamatud teemal:
Püsilink: https://www.kriso.ee/db/9783662585634.html
This volume brings together the latest basic and clinical research examining the effects and underlying mechanisms of psychedelic drugs. Examples of drugs within this group include LSD, psilocybin, and mescaline. Despite their structural differences, these compounds produce remarkably similar experiences in humans and share a common mechanism of action.  Commonalities among the substances in this family are addressed both at the clinical and phenomenological level and at the basic neurobiological mechanism level. To the extent possible, contributions relate the clinical and preclinical findings to one another across species. The volume addresses both the risks associated with the use of these drugs and the potential medical benefits that might be associated with these and related compounds.

Arvustused

This book brings together the latest basic and clinical research into the underlying mechanism of action, effects, and possible clinical uses of psychedelic drugs. It brings together current knowledge regarding this class of drugs pharmacology, neurobiological effects, subjective experience, and therapeutic effects. It brings together preclinical and clinical data, which will be of interest to anyone involved with or curious about this category of drugs. (Michael Easton, Doody's Book Reviews, September, 2018)

Preface.- Chemistry and structure-activity relationships of
psychedelics.- Hallucinogens and serotonin 5-HT2A receptor-mediated signaling
pathways.- Effects of hallucinogens on neuronal activity.- Interactions of
Hallucinogens with the Glutamatergic System:  Permissive Network Effects
Mediated Through Cortical Layer V Pyramidal Neurons.- The effects of
hallucinogens on gene expression.- Effect of Hallucinogens on Unconditioned
Behavior.- Hallucinogens in Drug Discrimination.- Phenomenology, structure
and dynamic of psychedelic states.- Serotonergic hallucinogen-induced visual
perceptual alterations.- New world tryptamine hallucinogens and the
neuroscience of ayahuasca.- Experimental psychosis research and schizophrenia
- similarities and dissimilarities in psychopathology.- A review of
Hallucinogen Persisting Perception Disorder (HPPD) and an exploratory study
of subjects claiming symptoms of HPPD.- Therapeutic applications of classic
hallucinogens.- Classic Hallucinogens and Mystical Experiences: Phenomenology
and Neural Correlates.